People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $495.3M | 2010 |
| Alloy Therapeutics, Inc. | — | Biotechnology | Series C | $116.7M | $736.9M | 2021 |
| Adimab, LLC | — | Biotechnology | Series A | $13.8M | $499.5M | 2012 |
| Adimab, Inc. | — | Biotechnology | Series A | $12.2M | $144.6M | 2009 |
| Cantai Therapeutics, Inc. | — | Biotechnology | Seed | $4.3M | $6.2M | 2026 |
Errik B. Anderson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Errik B. Anderson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tillman U. Gerngross | 3 | 5 |
| Robert L. Birnbaum | 3 | 4 |
| Terrance L. McGuire | 3 | 3 |
| William J Maris | 2 | 3 |
| Michael L. Ross | 2 | 3 |
| Carl Gordon | 1 | 24 |
| Michael Ross | 1 | 18 |
| Amy Schulman | 1 | 11 |
| Terrance McGuire | 1 | 9 |
| Errik Anderson | 1 | 8 |
| Geeta Vemuri | 1 | 7 |
| CARL L. GORDON | 1 | 7 |
| Michael Gray | 1 | 6 |
| Michael Wyzga | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Claudio Nessi | 1 | 5 |
| Daniel Burgess | 1 | 4 |
| William Aliski | 1 | 4 |
| Paula Ragan | 1 | 3 |
| Alison Lawton | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.